Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kastelein, J. J.P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kastelein, J. J.P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

The realities of dyslipidaemia: what do the studies tell us?

John J.P. Kastelein*

Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands

* Corresponding author. Tel: +31 20 566 6612; fax: +31 20 566 9343. E-mail address: e.vandongen{at}amc.uva.nl

Well-designed studies have established the benefits of statins in populations with widely differing overall cardiovascular risk. Statins reduce LDL-cholesterol in all of these populations, in some cases to a level well below guideline targets. The effects of statins on cardiovascular outcomes are remarkably similar between studies, with the incidence of cardiovascular events reduced relative to placebo by not more than ~40% in any study and usually by ~10–30%. Addressing other cardiovascular risk factors will be necessary to generate additional benefits. Atherosclerosis is increasingly considered an inflammatory disease, and reducing markers of inflammation, such as C-reactive protein, may prove beneficial. However, intervention with agents that increase HDL-cholesterol is already supported by substantial clinical evidence. A number of well-designed evaluations of fibrates and nicotinic acid, which act mainly by raising levels of HDL-cholesterol, have demonstrated significant improvements in outcomes in populations at high risk of cardiovascular events. Combinations of nicotinic acid with a statin have been shown to halt or reverse the progression of atherosclerosis, in the HDL Atherosclerosis Treatment Study (HATS) and in the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2 trial. Nicotinic acid–statin combination therapy has produced the largest improvements in clinical outcomes so far achieved, with a reduction in cardiovascular events of 60–90% relative to placebo in HATS. Nicotinic acid-based combinations are a rational and an evidence-based approach to improve cardiovascular outcomes to a greater extent than is currently possible with statins alone.

Key Words: HDL-cholesterol • Atherosclerosis • Cardiovascular risk • Dyslipidaemia • Evidence-based medicine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
B. G. Brown
Niaspan(R) in the management of dyslipidaemia: the evidence
Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F60 - F67.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.